A Phase 2 interventional study of Alfimeprase in Catheters, Indwelling, sponsored by ARCA Biopharma, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-02-03.
Sponsored by ARCA Biopharma, Inc. · Phase 2, Interventional, and Treatment
This trial is for patients with a central venous catheter (a vascular access device) that is not functioning properly (unable to withdraw blood). The trial compares a new blood clot dissolving agent (alfimeprase) against the currently used treatment.
1,528 studies on the registry are indexed under Thrombosis; 240 are open to participants now.
This study's enrollment of 115 is close to the median of 107 across 866 interventional studies indexed under Thrombosis.
Browse Thrombosis studies →ARCA Biopharma, Inc. is the lead sponsor of 12 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Subjects must:
This study is completed, as verified in Jun 2005. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alfimeprase
ARCA Biopharma, Inc.